Beijing-headquartered venture capital firm Legend Capital has led the RMB200 million ($29 million) Series A funding of Chinese drug developer Sciwind Biosciences, which is focused on treating metabolic disorders, China Money Network reported.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
